Literature DB >> 17536304

Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis.

Emine Cagnur Ulukus1, H Aydanur Kargi, Banu Sis, Banu Lebe, Ilhan Oztop, Atilla Akkoclu, Ahmet Onen, Aydin Sanli.   

Abstract

The role of survivin that regulates the biological behavior of non-small-cell lung carcinoma (NSCLC) is still controversial. We aimed to investigate survivin expression in NSCLC and to define any correlation with expressions of p53, bcl-2, bax, apoptotic index (AI), tumor cell proliferation, clinicopathologic variables, and overall survival. Tumors of 63 patients with NSCLC were examined for expressions of survivin, p53, bcl-2, bax, and Ki-67 by immunohistochemistry. AI was also evaluated. Results for each antibody were correlated with each other, and with clinicopathologic variables including age, sex, histologic subtype, TNM (T: primary tumor, N: regional lymph node metastasis, M: distant metastasis) stage, lymph node status, smoking history, and prognosis. Nuclear survivin expression was inversely correlated with p53 expression (P = 0.04, r = - 0.367), and tumor stage (P = 0.03, r = - 0.273), and positively correlated with tumor cell proliferation (P = 0.009, r = 0.329). Cytoplasmic survivin expression positively correlated with smoking history (P = 0.02, r = 0.282). Survivin/bax ratio was inversely correlated with AI (r: - 0.004). By Kaplan-Meier analysis, TNM stage (P < or = 0.001), lymph node metastasis (P = 0.04), and Ki-67 index (P < or = 0.001) were associated with survival, whereas survivin was not. In multivariate analysis, only TNM stage was an independent predictor. Although survivin and other apoptosis-related protein expressions fail to predict the clinical outcome, the present findings suggest that survivin is involved in tumor cell apoptosis and proliferation and may play a role in critical steps of cancer progression in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17536304     DOI: 10.1097/01.pai.0000201808.35931.78

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  7 in total

1.  The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.

Authors:  Anjaiah Srirangam; Monica Milani; Ranjana Mitra; Zhijun Guo; Mariangellys Rodriguez; Hitesh Kathuria; Seiji Fukuda; Anthony Rizzardi; Stephen Schmechel; David G Skalnik; Louis M Pelus; David A Potter
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

2.  Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer.

Authors:  C Xiaoyuan; C Longbang; W Jinghua; G Xiaoxiang; G Huaicheng; Z Qun; S Haizhu
Journal:  Ir J Med Sci       Date:  2009-11-17       Impact factor: 1.568

3.  Expression of survivin and patients survival in non-small cell lung cancer: a meta-analysis of the published studies.

Authors:  Li-Nian Huang; Dong-Sheng Wang; Yu-Qing Chen; Cheng-Ling Zhao; Bei-Lei Gong; An-Bang Jiang; Wei Jia; Feng-Dan Hu
Journal:  Mol Biol Rep       Date:  2012-10-13       Impact factor: 2.316

4.  High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.

Authors:  Valsamo K Anagnostou; Frank J Lowery; Vassiliki Zolota; Vassiliki Tzelepi; Arun Gopinath; Camil Liceaga; Nikolaos Panagopoulos; Konstantina Frangia; Lynn Tanoue; Daniel Boffa; Scott Gettinger; Frank Detterbeck; Robert J Homer; Dimitrios Dougenis; David L Rimm; Konstantinos N Syrigos
Journal:  BMC Cancer       Date:  2010-05-09       Impact factor: 4.430

5.  miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5.

Authors:  Qiang Fu; Jun Zhang; Xin Xu; Fei Qian; Ke Feng; Jie Ma
Journal:  Tumour Biol       Date:  2016-10-06

6.  Association of survivin polymorphisms with tumor susceptibility: a meta-analysis.

Authors:  Ying Zhu; Yongguo Li; Shisheng Zhu; Renkuan Tang; Yunzhi Liu; Jianbo Li
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

7.  Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer.

Authors:  Michał Szczyrek; Radosław Mlak; Aneta Szudy-Szczyrek; Kamila Wojas-Krawczyk; Karolina Kędziora; Janusz Milanowski
Journal:  Cells       Date:  2022-03-10       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.